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The IASLC Staging and Prognostic Factors Committee has
collected a new database of 94,708 cases donated from 35
sources in 16 countries around the globe. This has now
been analysed by our statistical partners at Cancer Research
And Biostatistics and, in close collaboration with the
members of the committee proposals have been developed
for the T, N, and M categories of the 8th edition of the TNM
Classiﬁcation for lung cancer due to be published late 2016.
In this publication we describe the methods used to eval-
uate the resultant Stage groupings and the proposals put
forward for the 8th edition.
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The seventh edition of the tumor, node, and metas-
tasis (TNM) classiﬁcation for lung cancer was published
in September 20091,2 and enacted in January 2010.3,4The revision was novel in that the changes were based
entirely on the proposals of the International Association
for the Study of Lung Cancer (IASLC) International
Staging Project.5–13 The project was organized and fun-
ded by the IASLC and collected and analyzed more than
100,000 cases contributed by colleagues at 46 centers in
more than 19 countries around the world. Data entry
and analysis were performed by Cancer Research and
Biostatistics (CRAB), a not-for-proﬁt organization based
in Seattle, Washington. Validation, both internal and
external, was more rigorous than that undertaken in any
previous revision.14 The success of this project led the
IASLC to expand the remit of its Staging and PrognosticJournal of Thoracic Oncology Vol. 11 No. 1: 39-51
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nizations, develop proposals for the eighth edition of the
TNM classiﬁcation for other thoracic malignancies in
addition to lung cancer.
In preparation for the impending eighth edition of
TNM staging for lung cancer, the committee and part-
ners in CRAB developed a new database. The char-
acteristics of the new database15 and the committee’s
proposals for changes to the T, N, and M descriptors16–18
have been published elsewhere; here we present
the proposals for the resultant TNM stage groupings.
All these proposals will be submitted to the Union for
International Cancer Control and the American Joint
Committee on Cancer for inclusion in the eighth
edition of the TNM classiﬁcation for lung cancer, which is
due to be published in late 2016 and enacted in
January 2017.Methods
During the transition from adopting the seventh
edition to working toward the eighth edition, a new data
dictionary was developed in conjunction with a new
Electronic Data Capture (EDC) system. Housed at CRAB,
the EDC system has provided a total of 4667 cases that
were used in this latest revision, and another 90,041
cases have been contributed by individual sites in
retrospective fashion and mapped to be compatible with
the EDC data ﬁelds.15 The database contains cases that
were treated using all modalities of care, including
multimodality treatment, and diagnosed between 1999
and 2010. For the analyses of TNM categories presented
here, only cases with a histologic diagnosis of non–small
cell lung cancer and complete staging information
were included. For cases in which chemotherapy was
received before surgery (yp cases), only clinical stage
was considered.
Candidate proposals for overall TNM stage groups
were developed in conjunction with proposed changes to
the T and M categories.16,17 The proposed changes are
highlighted in the full list of T, N, and M descriptors
shown in Table 1, which also incorporates the subse-
quent recommendations of the IASLC on classiﬁcation of
minimally invasive adenocarcinoma.18 The existing N
descriptors were validated, and no changes were pro-
posed for the eighth edition.19
The new T and M proposals were applied to the
training data set, and the resultant TNM subsets and
the numbers of cases in each subset by clinical stage
and pathologic stage are shown in Tables 2 and 3. A
small number of candidate stage grouping schemes
were developed initially on the basis of the M0 cases
by using a recursive partitioning and amalgamation
algorithm.20 The analysis was applied using thestatistical package R, Version 3.1.0 (R Project for
Statistical Computing, Vienna, Austria). The algorithm
generates a tree-based model for the survival data
using log-rank test statistics for recursive partitioning
and, for selection of the important groupings, boot-
strap resampling to correct for the adaptive nature of
the splitting algorithm (Fig. 1). The tree-based anal-
ysis was stratiﬁed on the basis of type of data sub-
mission: registry versus all others. The analysis
grouped cases on the basis of the best
stage (pathologic if available, otherwise clinical) after
determination of best split points on the basis of
overall survival using an ordered variable for the
newly proposed T categories and the current N cat-
egories (excluding NX cases). This analysis was per-
formed on a randomly selected training set
comprising two-thirds of the available data that met
the requirements for conversion to the newly pro-
posed T and M categories (N ¼ 25,911 M0 cases plus
599 M1 cases), with 12,931 cases reserved for sub-
sequent internal validation. The random selection
process was stratiﬁed by type of database submission
and time period of case entry (1999–2004 versus
2005–2010). M1 cases were also split but were not
the focus of the tree-based analysis.
An ordered list of groupings was constructed from
the terminal nodes of the survival tree. With this list as a
guide, several proposed stage groupings were created by
combining adjacent groups. Selection of a ﬁnal stage
grouping proposal from among the candidate schemes
was based on its statistical properties in the training set
and relevance to clinical practice and was arrived at by
consensus.
Candidate TNM stage grouping schemes were
evaluated in part by assessing overall survival by
clinical, pathologic, and best stage. Survival was
measured from the date of diagnosis for clinically
staged tumors and from the date of surgery for
pathologically staged tumors and calculated by the
Kaplan-Meier method. Adjusted survival curves21,22
were drawn using inverse probability weights
applied to the survival calculations on the basis of
the proportion of cases that were from registry da-
tabases (versus others) in each stage category. This
method was used in light of the different overall
survival prognosis in registry databases in general,
combined with the disproportionate representation of
registry cases in some of the stage groups. Contrasts
between adjacent stage groups were evaluated by
Cox regression analysis, adjusted for baseline factors
(age, performance status, and cell type) and type
of database submission by using the SAS System
for Windows Version 9.4 PHREG procedure (SAS,
Cary, NC).
Table 1. Proposed T, N, and M descriptors for the eighth edition of TNM classiﬁcation for lung cancer
T: Primary tumor
Tx Primary tumor cannot be assessed or tumor proven by presence of malignant cells in sputum
or bronchial washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor 3 cm in greatest dimension surrounded by lung or visceral pleura without bronchoscopic
evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)a
T1a(mi) Minimally invasive adenocarcinomab
T1a Tumor £1 cm in greatest dimensiona
T1b Tumor >1 cm but £2 cm in greatest dimensiona
T1c Tumor >2 cm but £3 cm in greatest dimensiona
T2 Tumor >3 cm but £5 cm or tumor with any of the following featuresc:
- Involves main bronchus regardless of distance from the carina but without involvement
of the carina
- Invades visceral pleura
- Associated with atelectasis or obstructive pneumonitis that extends to the hilar region,
involving part or all of the lung
T2a Tumor >3 cm but £4 cm in greatest dimension
T2b Tumor >4 cm but £5 cm in greatest dimension
T3 Tumor >5 cm but £7 cm in greatest dimension or associated with separate tumor nodule(s)
in the same lobe as the primary tumor or directly invades any of the following structures:
chest wall (including the parietal pleura and superior sulcus tumors), phrenic nerve,
parietal pericardium
T4 Tumor >7 cm in greatest dimension or associated with separate tumor nodule(s) in a different
ipsilateral lobe than that of the primary tumor or invades any of the following structures:
diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus,
vertebral body, and carina
N: Regional lymph node involvement
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary
nodes, including involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene,
or supraclavicular lymph node(s)
M: Distant metastasis
M0 No distant metastasis
M1 Distant metastasis present
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s)
or malignant pleural or pericardial effusiond
M1b Single extrathoracic metastasise
M1c Multiple extrathoracic metastases in one or more organs
Note: Changes to the seventh edition are in bold.
aThe uncommon superﬁcial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend
proximal to the main bronchus, is also classiﬁed as T1a.
bSolitary adenocarcinoma,  3cm with a predominately lepidic pattern and  5mm invasion in any one focus.
cT2 tumors with these features are classiﬁed as T2a if 4 cm in greatest dimension or if size cannot be determined, and T2b if >4 cm but
5 cm in greatest dimension.
dMost pleural (pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple microscopic examinations of
pleural (pericardial) ﬂuid are negative for tumor and the ﬂuid is nonbloody and not an exudate. When these elements and clinical judgment
dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor.
eThis includes involvement of a single distant (nonregional) lymph node.
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Figure 1 shows the survival tree based on best stage
in the training set with M0 cases only (N ¼ 25,911). The
ordered list of terminal nodes, with stratiﬁed hazard
ratios relative to the best prognosis node (T1aN0), is
shown in Table 4. The proposed eighth edition of theTNM stage groupings are summarized in Table 5, in
which those TNM subsets that the proposals advocate
moving from their present stage grouping are high-
lighted. The transfer of some cases from within a cate-
gory in the present staging system to another in the
proposals for the eighth edition of the TNM classiﬁcation
Table 2. Distribution of T, N, and M categories in the
training set (clinical classiﬁcation)
Proposed T/M
categories
N category
TotalN0 N1 N2 N3
T1a 781 7 19 6 813
T1b 3105 68 124 30 3327
T1c 2417 142 208 32 2799
T2a 1928 268 372 50 2618
T2b 585 131 183 36 935
T3 837 191 344 77 1449
T4 1711 392 1642 909 4654
M1a 64 9 77 127 277
M1b 39 16 67 85 207
M1c 67 15 120 196 398
Total 11,534 1239 3156 1548 17,477
T, tumor; N, node; M, metastasis.
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to the migration of certain TNM subsets between stage
groups. For example, an N0 case that involves either
diaphragm invasion or a 7-cm tumor that is classiﬁed as
T3 according to the deﬁnitions in the seventh edition,
moves from stage IIB to IIIA by virtue of being redeﬁned
as T4 by the eighth edition. A new stage, IIIC, consists of
T3–T4N3M0 cases, which showed a worse prognosis
than the others. The numbers of available cases (training
and validation sets combined) occupying each of these T,
N, and M categories by best stage are shown in Table 6.
Figures 2 and 3 show weighted survival by stage
according to the seventh edition of TNM and the newly
proposed TNM stage based on the entire set of cases
available for reclassiﬁcation, including the M1 cases:
17,477 cases clinically staged I–IV and 31,836 cases with
a pathologic stage. Tables 7 and 8 show the statistics
from adjusted Cox proportional hazards regression
modeling based on the seventh edition of TNM and the
proposed new system for clinical and pathologic stage,
respectively, using the new database collected for the
eighth edition. The hazard ratios between adjacent stageTable 3. Distribution of T, N, and M categories in the
training set (pathologic classiﬁcation)
Proposed T/M
categories
N categories
TotalN0 N1 N2 N3
T1a 1390 45 49 2 1486
T1b 5638 311 392 7 6348
T1c 4403 484 515 13 5415
T2a 6102 1223 1526 55 8906
T2b 1640 485 490 16 2631
T3 2683 795 1025 39 4542
T4 1447 546 613 30 2636
Total 23,303 3889 4610 162 31,964
T, tumor; N, node; M, metastasis.group categories are uniformly signiﬁcant for stage in
both the seventh edition and the more ﬁnely parsed
proposed eighth edition. The additional stage categories
within stage I and stage III in the proposed system are
sufﬁciently distinct from one another. The weighted
clinical survival estimates for the proposed eighth
edition (Fig. 2B) show overlap between stages IIIC (T3–
T4N3) and IVA (M1a cases with metastases restricted to
the thoracic cavity and M1b cases with single metastasis
outside the thoracic cavity). This overlap is not evident
in the multivariate analyses, in which the hazard ratio for
the comparison between stage IVA and stage IIIC is 1.75
(p < 0.0001). The overlap in the survival curves may be
partly a result of the distribution of registry and non-
registry cases despite the attempt to correct for this by
weighting. There are no registry cases in the stage IV
groups, which had to have a sufﬁcient description of
metastatic disease to be classiﬁed as M1a, M1b, or M1c.
For both the clinical and pathologic stagemodels, there
is a slight increase in the value for R2, which is an estimate
of the percent variance explained23 by the models
described earlier, for the proposed eighth edition of the
staging scheme. For clinical stage, the R2 value for the
seventh edition of the staging scheme in the complete data
set is 67.5. The R2 value for the scheme in the proposed
eighth edition is 68.3. Likewise, for pathologic stage, the R2
value for the seventh edition of the classiﬁcation is 45.7
versus 46.9 for the proposed classiﬁcation.
The proposed stage groupings are summarized in
Table 9.Validation
The proposals derived from the training set were
internally validated against the validation set of 12,931
cases (5785 classiﬁable by clinical stage and 10,558
classiﬁable by pathologic stage). The validation set
generated survival curves that were generally similar to
those in the training set, and the Cox proportional hazards
regression analyses that calculated the hazard ratios be-
tween each pair of adjacent stage groups while controlling
for cell type, sex, age, and database type were all statis-
tically signiﬁcant for the clinical and the pathologic stag-
ing data, with one exception. The comparison of clinical
stage IIA versus IB disease was not signiﬁcant, with a
hazard ratio of 1.35 and a p value of 0.18. The hazard
risk is slightly higher than that found when analyzing
the combined training and validation sets; however, the
p value is reduced, possibly because the validation set
contains only 183 cases in the clinical stage IIA.
External validation against an outside database is
desirable. In this regard, the North American Surveil-
lance, Epidemiology, and End Results Registries (SEER)
database was a valuable tool for development of the
Figure 1. Recursive partitioning and amalgamation-generated survival tree based on best stage for 25,911 M0 training set
cases. T and N categories are modeled as ordered variables. Stratiﬁed hazard ratios are given relative to the leftmost ter-
minal node, T1aN0.
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in the SEER data cannot be classiﬁed. Although addi-
tional site-speciﬁc factors have been collected during
recent years (2010–2012), it is, for example, impossibleTable 4. Terminal nodes deﬁned on the basis of best stage
from a stratiﬁed tree-based analysis (recursive partitioning
analysis) of the training data set. Hazard ratios are relative
to the best prognosis group (T1aN0) and are stratiﬁed on
type of database submission: registry versus others
Terminal
node
Sample size
(training set)
Hazard
ratio
T1a N0 1223 1.00
T1b N0 4140 1.55
T1c N0 3098 2.07
T2a N0 4316 2.83
T2b N0 1139 3.89
T3 N0 1965 5.08
T1a–T2b N1 1755 5.09
T3 N1 558 7.56
T1a–T2b N2 2226 7.82
T4 N0–N1 2459 10.10
T1a–T2b N3 127 14.08
T3–T4 N2 2229 14.34
T3–T4 N3 676 21.73
T, tumor; N, node.to identify and reclassify cases with diaphragm invasion
that were classiﬁed as T3 in the seventh edition. In any
case, given the fact that the additional site-speciﬁc fac-
tors were not in effect for earlier years, too few cases
with the appropriate time frame are available to be
classiﬁed. The SEER data have been classiﬁed according
to the seventh edition, however. Consequently, a com-
parison of the IASLC database with SEER from the
standpoint of overall survival across stage categories in
the seventh edition was performed to assess the validity
of the IASLC database.
Supplemental Figure 1 shows survival according to
stage in the seventh edition for the SEER database and
the IASLC database. Stage for stage, the median survival
time is consistently higher in the IASLC database, which
is not unexpected given the various data sources, only a
portion of which originated from a national registry.
When the difference in survival between the SEER data
and the IASLC data is explored by using Cox regression
analysis with stage and member database as factors,
however, adjusting for surgical management diminishes
the difference between the two databases. The adjusted
hazard ratio for overall survival is 0.91 in favor of the
IASLC database (95% conﬁdence interval 0.85–0.96,
p < 0.0001). The analysis data set for TNM stage from
the IASLC database is 87% surgically managed cases
Table 5. Descriptors and T and M categories in the seventh edition and as proposed for the eighth editiona
N categories
Overall stage
Descriptor in 7th edition Proposed T/M N0 N1 N2 N3
T1  1 cm T1a IA1 (IA) IIB (IIA) IIIA IIIB
T1 > 1–2 cm T1b IA2 (IA) IIB (IIA) IIIA IIIB
T1 > 2–3 cm T1c IA3 (IA) IIB (IIA) IIIA IIIB
T2 > 3–4 cm T2a IB IIB (IIA) IIIA IIIB
T2 > 4–5 cm T2b IIA (IB) IIB (IIA) IIIA IIIB
T2 > 5–7 cm T3 IIB (IIA) IIIA (IIB) IIIB (IIIA) IIIC (IIIB)
T3 structures T3 IIB IIIA IIIB (IIIA) IIIC (IIIB)
T3 > 7 cm T4 IIIA (IIB) IIIA IIIB (IIIA) IIIC (IIIB)
T3 diaphragm T4 IIIA (IIB) IIIA IIIB (IIIA) IIIC (IIIB)
T3 endobronchial: location/atelectasis 3–4 cm T2a IB (IIB) IIB (IIIA) IIIA IIIB
T3 endobronchial: location/atelectasis 4–5 cm T2b IIA (IIB) IIB (IIIA) IIIA IIIB
T4 T4 IIIA IIIA IIIB IIIC (IIIB)
M1a M1a IVA (IV) IVA (IV) IVA (IV) IVA (IV)
M1b single lesion M1b IVA (IV) IVA (IV) IVA (IV) IVA (IV)
M1c multiple lesions M1c IVB (IV) IVB (IV) IVB (IV) IVB (IV)
aWhere there is a change, the resultant stage groupings proposed for the eighth edition are in bold, and the stage in the seventh edition is
given in parenthesis.
T, tumor; M, metastasis.
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The unadjusted hazard ratio is 0.73 (95% conﬁdence
interval 0.68–0.77).
Discussion
This publication sets out the IASLC proposals for
stage groupings in the eighth edition of the TNMTable 6. Sample sizes for TNM subsets providing the basis for
Descriptor in
seventh edition
Proposed
T/M
N0 N1
Overall
stage
Sample
size
Ove
sta
T1  1 cm T1a IA  IA1 1765 IIA
T1 > 1–2 cm T1b IA  IA2 6127 IIA
T1 > 2–3 cm T1c IA  IA3 4606 IIA
T2 > 3–4 cm T2a IB 6382 IIA
T2 > 4–5 cm T2b IB  IIA 1689 IIA
T2 > 5–7 cm T3 IIA  IIB 1244 IIB
T3 structures T3 IIB 1666 IIIA
T3 > 7 cm T4 IIB  IIIA 870 IIIA
T3 diaphragm T4 IIB  IIIA 47 IIIA
T3 endobronchial
location/atelectasis
>3–4 cm T2a IIB  IB 18 IIIA
>4–5 cm T2b IIB  IIA 11 IIIA
T4 T4 IIIA 1862 IIIA
M1a M1a IV  IVA 62 IV 
M1b single lesion M1b IV  IVA 38 IV 
M1b multiple lesions M1c IV  IVB 59 IV 
TNM, tumor, node, metastasis.Classiﬁcation for Lung Cancer. The database used in this
analysis consisted entirely of cases of non–small cell lung
cancer; a separate publication addresses the recom-
mendations for small cell lung cancer.24
The IASLC Staging and Prognostic Factors Commit-
tee remains committed to the accumulation of pro-
spectively acquired data using the data set speciﬁcallyproposed changes, best stage
N2 N3
rall
ge
Sample
size
Overall
stage
Sample
size
Overall
stage
Sample
size
 IIB 47 IIIA 59 IIIB 4
 IIB 321 IIIA 444 IIIB 20
 IIB 492 IIIA 596 IIIB 37
 IIB 1250 IIIA 1666 IIIB 89
 IIB 497 IIIA 559 IIIB 35
 IIIA 418 IIIA  IIIB 455 IIIB  IIIC 45
432 IIIA  IIIB 736 IIIB  IIIC 55
316 IIIA  IIIB 320 IIIB  IIIC 33
16 IIIA  IIIB 22 IIIB  IIIC 0
 IIB 18 IIIA 10 IIIB 1
 IIB 2 IIIA 9 IIIB 1
538 IIIB 1770 IIIB  IIIC 893
IVA 11 IV  IVA 100 IV  IVA 145
IVA 13 IV  IVA 68 IV  IVA 74
IVB 18 IV  IVB 128 IV  IVB 191
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7th Ed. Events / N MST
24 
Month
60 
Month
IA 1119 / 6303 NR 93% 82%
IB 768 / 2492 NR 85% 66%
IIA 424 / 1008 66.0 74% 52%
IIB 382 / 824 49.0 64% 47%
IIIA 2139 / 3344 29.0 55% 36%
IIIB 2101 / 2624 14.1 34% 19%
IV 664 / 882 8.8 17% 6%
Proposed Events / N MST
24 
Month
60 
Month
IA1 68 / 781 NR 97% 92%
IA2 505 / 3105 NR 94% 83%
IA3 546 / 2417 NR 90% 77%
IB 560 / 1928 NR 87% 68%
IIA 215 / 585 NR 79% 60%
IIB 605 / 1453 66.0 72% 53%
IIIA 2052 / 3200 29.3 55% 36%
IIIB 1551 / 2140 19.0 44% 26%
IIIC 831 / 986 12.6 24% 13%
IVA 336 / 484 11.5 23% 10%
IVB 328 / 398 6.0 10% 0%
A B
Figure 2. Overall survival by clinical stage according to the seventh edition (A) and the proposed eighth edition (B) groupings
using the entire database available for the eighth edition. MST, median survival time. Survival is weighted by type of database
submission: registry versus other.
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tion.25 However, the added complexity of such data
accrual has resulted in our continuing to depend
largely on retrospective accrual of data that were
collected mostly for other purposes. The committee
accepted the advice of its statisticians and epidemi-
ologists that new cases be kept separate from the
data accrued for the seventh edition. This decision
has been vindicated by the improved survival by
stage for the newly acquired data set. This improved
survival may reﬂect improvements in diagnosis, such
as the increasing vogue for computed tomography
(CT) screening; improvements in the staging algo-
rithm with the widespread use of positron emission
tomography scanning and less invasive mediastinal
staging by endobronchial ultrasound and endoscopic
ultrasound; and improvements in treatment,
including the following: the use of adjuvant therapy
after complete resection, the availability of radical
options for treating less ﬁt individuals with stereo-
tactic body radiation therapy and minimally invasive
surgical options, and targeted agents providing
improved results in stage IV disease because their
toxicity proﬁle allows consideration of such treat-
ment in patients with worse performance levels.
Differences also exist between the data sets devel-
oped for the revisions leading to the seventh and
eighth editions of the TNM classiﬁcation for lungcancer, however. The new data set has a higher
proportion of cases from Asia—mostly from Japan,
which contributed 41% of the total—and this differ-
ence has in turn resulted in the proportion of cases
including surgery as a component of their treatment
rising from 53% in the previous data set to 85% in
the new one. In addition, there was an increase in the
proportion of cases derived from registry data and a
lack of cases from clinical trials. The net effect of all
these variations was that although stage-for-stage
survival increased in all stages, there was a relative
worsening of survival for advanced stages, especially
stage IIIB. We attempted to correct these biases by
performing the tree-based analysis stratiﬁed by type
of database and adjusting the survival curves by in-
verse probability weighting.
Changes to some T and M descriptors will result in
these cases being assigned to a different stage than
that to which they would have been assigned in the
seventh edition. In addition, some TNM subsets have
been moved to a new stage grouping. Although such
changes might raise the issue of whether consequent
changes to treatment algorithms are needed, it is
important to remind ourselves that stage does not
dictate treatment. Stage is one, and perhaps the single
most important, of several prognostic factors that
guide the appropriate treatment option(s) to offer
the patient. Any change to established treatment
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7th Ed. Events / N MST
24 
Month
60 
Month
IA 1837 / 11423 NR 94% 83%
IB 2168 / 7711 NR 87% 71%
IIA 1514 / 3702 NR 77% 57%
IIB 1325 / 2776 58.9 70% 49%
IIIA 3467 / 5818 35.0 61% 36%
IIIB 364 / 506 20.0 45% 23%
Proposed Events / N MST
24 
Month
60 
Month
IA1 139 / 1389 NR 97% 90%
IA2 823 / 5633 NR 94% 85%
IA3 875 / 4401 NR 92% 80%
IB 1618 / 6095 NR 89% 73%
IIA 556 / 1638 NR 82% 65%
IIB 2175 / 5226 NR 76% 56%
IIIA 3219 / 5756 41.9 65% 41%
IIIB 1215 / 1729 22.0 47% 24%
IIIC 55 / 69 11.0 30% 12%
A B
Figure 3. Overall survival by pathologic stage according to the seventh edition (A) and the proposed eighth edition (B)
groupings using the entire database available for the eighth edition. MST, median survival time. Survival is weighted by type
of database submission: registry versus other.
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informed by prospective trials.
The seventh edition of the TNM classiﬁcation for
lung cancer placed additional emphasis on tumor size
and, as could have been anticipated, size cut points
have further proliferated in the proposals for the eighthTable 7. Cox proportional hazards regression model output
for the seventh edition of the TNM classiﬁcation and
proposed eighth edition clinical stage groupings using the
entire database available for the eighth edition. Adjusted
for age (70 years or older), sex, and histologic diagnosis
(adenocarcinoma versus others). Stratiﬁed by type of
database submission (registry versus others)
Stages
Compared
Hazard ratio p
7th
edition
Proposed
8th edition
7th
edition
Proposed
8th edition
IA2 vs. IA1 — 1.82 — <0.0001
IA3 vs. IA2 — 1.40 — <0.0001
IB vs. IA 1.75 — <0.0001 —
IB vs. IA3 — 1.29 — <0.0001
IIA vs. IB 1.57 1.30 <0.0001 0.0012
IIB vs. IIA 1.22 1.30 0.0046 0.0008
IIIA vs. IIB 1.28 1.48 <0.0001 <0.0001
IIIB vs. IIIA 1.57 1.38 <0.0001 <0.0001
IIIC vs. IIIB — 1.36 — <0.0001
IVA vs. IIIC — 1.75 — <0.0001
IVB vs. IVA — 1.91 — <0.0001
IV vs. IIIB 2.61 — <0.0001 —
TNM, tumor, node, metastasis.edition, such that size will now be a descriptor in all
T categories.
Some new stage groupings are proposed for the eighth
edition of the TNM classiﬁcation for lung cancer. The di-
vision of the category T1 into T1a, T1b, and T1c on the
basis of new size cut points of 1 cm and 2 cm has resulted
in these cases (when associated with the categories N0
and M0) being assigned to stage IA1, IA2, and IA3,
respectively, and thus reﬂecting the statistically differentTable 8. Cox proportional hazards regression model output
for the seventh edition of the TNM classiﬁcation and
proposed eighth edition pathologic stage groupings using
the entire database available for the eighth edition.
Adjusted for age (70 years or older), sex, histologic
diagnosis (adenocarcinoma versus others), and type of
database submission (registry versus others)
Comparison
Hazard ratio p
7th
edition
Proposed
8th edition
7th
edition
Proposed
8th edition
IA2 vs. IA1 — 1.44 — <0.0001
IA3 vs. IA2 — 1.31 — <0.0001
IB vs. IA 1.68 — <0.0001 —
IB vs. IA3 — 1.32 — <0.0001
IIA vs. IB 1.66 1.29 <0.0001 <0.0001
IIB vs. IIA 1.22 1.40 <0.0001 <0.0001
IIIA vs. IIB 1.61 1.66 <0.0001 <0.0001
IIIB vs. IIIA 1.58 1.67 <0.0001 <0.0001
IIIC vs. IIIB — 1.85 — <0.0001
TNM, tumor, node, metastasis.
Table 9. Proposed stage groupings for the eighth edition of
the TNM classiﬁcation for lung cancer
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA1 T1a(mi) N0 M0
T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a–c N1 M0
T2a N1 M0
T2b N1 M0
T3 N0 M0
Stage IIIA T1a–c N2 M0
T2a–b N2 M0
T3 N1 M0
T4 N0 M0
T4 N1 M0
Stage IIIB T1a–c N3 M0
T2a–b N3 M0
T3 N2 M0
T4 N2 M0
Stage IIIC T3 N3 M0
T4 N3 M0
Stage IVA Any T Any N M1a
Any T Any N M1b
Stage IVB Any T Any N M1c
Note: Changes to the seventh edition are highlighted in bold and
underlined.
TNM, tumor, node, metastasis; Tis, carcinoma in situ; T1a(mi),
minimally invasive adenocarcinoma.
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stage groupings should be used in any trials of novel
therapies, such as sublobar resection and nonsurgical
treatment options. They should not in themselves be taken
as a constraint on the use of structured surveillance in
studies of CT screening because the proportion of screen-
detected tumors in our data set is unknown.
A new stage grouping has also been created for the
most advanced local disease categories, T3 and T4
associated with N3 disease but category M0. Such cases
will now be classiﬁed as stage IIIC, reﬂecting their worse
outcome than that of cases involving tumors that remain
in stage IIIB. The prognosis for stage IIIC cases is similar
to that for stage IVA cases, but the separation is justiﬁed
by the different treatment approaches used in such
cases.
Finally, changes to classiﬁcation of stage IV disease
have been proposed. Cases with intrathoracic metastatic
disease to the contralateral lung or with pleural/peri-
cardial dissemination will remain classiﬁed as M1a dis-
ease. The category M1b will now be assigned to cases
with is a single metastatic deposit (in one organ), and
M1a and M1b cases will be moved to a new stage
grouping, stage IVA. Although the survival rates in thesetwo M1 categories are sufﬁciently similar to justify their
inclusion in a single stage grouping, the committee
believed that it would be useful to retain the separate M
categories M1a and M1b for future data collection and
analysis because some patients with oligometastatic
disease are now receiving more aggressive local therapy
in addition to systemic treatment. The more common
situation involving multiple metastatic deposits, usually
in more than one organ, will now be classiﬁed as M1c
and staged as IVB.
Other changes to the stage groupings have been
proposed. In some cases, the change will result from a
T descriptor being allocated to a higher stage in the
eighth edition, such as has occurred with T3 tumors,
which have been thus classiﬁed because of invasion of
the chest wall or some mediastinal structures when
associated with N2 disease moving from stage IIIA
in the seventh edition to IIIB in the eighth and, when
associated with N3 disease, moving from stage IIIB to
IIIC. Similarly, all subdivisions of the category T1 that
are now associated with N1 disease will move from
stage IIA to IIB. In other situations tumors may be
allocated to a different T category in the eighth edi-
tion, which results in a change of stage as for the
reclassiﬁcation of tumors associated with diaphrag-
matic invasion to T4, and hence when associated with
N0 disease, moving from stage IIB to IIIA. For some T
and N categories both inﬂuences may affect the stage
grouping assigned to a case. For example, the shift of
tumors larger than 5 cm from T2b to T3 led to them
being assigned to a higher stage grouping whatever
the N category. When associated with N0 and N1
disease, such tumors move from IIA to IIB and from
IIB to IIIA, respectively, because of the change in T
category, whereas when they are associated with N2
or N3 disease, the shift from IIIA to IIIB and from IIIB
to IIIC is the result of the change of stage that has
been proposed for that TNM subset in the eighth
edition.
Like the seventh edition, the eighth edition includes
instances in which the power of the data requires
changes that at ﬁrst sight might appear counterintuitive.
The transfer of tumors larger than 5 cm to the T3 cate-
gory, leaving T2a for tumors larger than 3 cm but no
larger than 4 cm and T2b for tumors larger than 4 cm
but no larger than 5 cm should, if a variant of stage
migration were in effect, result in a lower stage being
assigned to these tumors for all N categories. In reality,
the new data set showed that such cases should remain
in the same stage grouping as assigned in the seventh
edition, except when T2a cases were associated with N1
disease, which would mean that a higher stage grouping
was appropriate. Will this change encourage wider
consideration of adjuvant chemotherapy after the
48 Goldstraw et al Journal of Thoracic Oncology Vol. 11 No. 1complete resection of such small tumors (4 cm and
smaller)? Such questions challenge us all to reconsider
the treatment algorithms and test new options with
appropriate clinical trials.
Central to the greater emphasis on tumor size as a
descriptor that is now proposed in all T categories is
the need to study an appropriate way in which to
measure size. Appropriate measurement of size is
especially important when dealing with mixed
attenuation tumors, which are being found increas-
ingly frequently as CT screening for lung cancer
becomes more widely adopted and with the recen-
tly revised classiﬁcation for adenocarcinoma. A
discussion document on this topic has been pub-
lished by the IASLC Staging and Prognostic Factors
Committee.18
When presenting its proposals for the seventh
edition of the TNM classiﬁcation for lung cancer, we
expressed the hope that through the support of the
pharmaceutical industry and with the cooperation
of its members and the generous donation of
hard-earned data, the IASLC could go on to develop
validated proposals for the eighth edition and beyond.
This article is an important step in realizing that
ambition.
As more detailed data are accrued, our survival an-
alyses will inevitably permit sharper distinction between
subsets within the present T, N, and M categories and the
resultant stage groupings, thereby leading to prolifera-
tion of such categories and stage groupings, as well as to
added complexity of the staging system. The IASLC
Staging and Prognostic Factors Committee has strived to
limit such changes to those that appear to have clinical
relevance. Even so, the changes proposed for the eighth
edition will further reduce backward compatibility
within existing databases. This fact is certain to be an
increasing issue with future revisions, and we can but
caution those collecting data to “future proof” their data
by collecting raw data wherever possible, especially
when documenting tumor size.
The Staging and Prognostic Factors Committee of the
IASLC presents these recommendations to inform the
discussions leading to the eighth edition of the TNM
classiﬁcation for lung cancer. We hope that the thoracic
oncology community ﬁnds the proposals of value and
that when accepted, they will have a positive impact on
the effectiveness of treatment for lung cancer, which will
beneﬁt patients around the globe.Appendix
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